FibroBiologics to Present Innovative Research at Major Conference
FibroBiologics, Inc. (NASDAQ: FBLG), a leading clinical-stage biotechnology firm, is gearing up to showcase its groundbreaking advancements at the 2024 Cell & Gene Meeting on the Mesa. With over 160 patents in development, this company is committed to creating therapeutics for chronic diseases using the regenerative capabilities of fibroblasts.
Exciting Developments in Chronic Disease Therapies
At the upcoming conference, scheduled for October 7-9, the Chief Scientific Officer, Dr. Hamid Khoja, plans to present findings on pre-clinical studies that are promising significant breakthroughs in chronic wound healing and psoriasis treatments. The focus will be on their innovative product candidate, CYWC628, which is a fibroblast spheroid designed for topical application.
Details of the Presentation
Dr. Khoja’s presentation is set for October 7, 2024, at 5:45 p.m. MST, in FLW Ballroom F. The details surrounding this presentation underline the company's commitment to advancing research that holds the potential to transform treatment protocols for chronic conditions.
Understanding Fibroblast Technology
Fibroblasts are critical cells that contribute to tissue repair and healing. By harnessing their capabilities, FibroBiologics aims to develop therapeutic strategies that not only address symptoms but also target the underlying causes of chronic diseases. This dual approach suggests a more holistic pathway to patient recovery.
Strategic Goals and Vision
As part of FibroBiologics' broader vision, the team is dedicated to accelerating their research and development efforts. The aim is to eventually transition successful product candidates into clinical trials, starting with the phase I/II diabetic foot ulcer clinical trials, showcasing their dedication to innovation in cell-based therapies.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company specializing in fibroblast cell research. The organization’s extensive patent portfolio spans various therapeutic areas, including orthopedics, cancer treatment, and regenerative medicine. As a pioneer in cell therapy, FibroBiologics is setting the stage for next-generation treatments that could reshape the landscape of chronic disease management.
Frequently Asked Questions
What is the focus of FibroBiologics’ presentation at the conference?
FibroBiologics will present their pre-clinical studies on chronic wound healing and psoriasis, highlighting their innovative fibroblast-derived therapeutic candidates.
Who is presenting for FibroBiologics at the conference?
Dr. Hamid Khoja, the Chief Scientific Officer of FibroBiologics, will be the presenter.
When and where is the Cell & Gene Meeting on the Mesa held?
The conference will take place from October 7-9, 2024, in Phoenix, Arizona, with Dr. Khoja's presentation scheduled for October 7.
What innovations is FibroBiologics pursuing?
The company is focusing on developing therapies for chronic diseases like diabetic foot ulcers through the use of fibroblast cell technologies.
How can I contact FibroBiologics for more information?
For inquiries, you can email FibroBiologics at info@fibrobiologics.com.
